Trial Profile

Phase I/II Study of CaspaCIDe® T Cells From an HLA-Partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 13 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rimiducid (Primary) ; Rivogenlecleucel (Primary)
Indications Acute myeloid leukaemia; Graft-versus-host disease; Haematological malignancies; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions
Sponsors Bellicum Pharmaceuticals

Most Recent Events

01 Oct 2020 Planned End Date changed from 1 Feb 2035 to 1 May 2034.
01 Oct 2020 Planned primary completion date changed from 1 Feb 2020 to 1 May 2021.
24 Oct 2019 Planned End Date changed from 1 Feb 2021 to 1 Feb 2035.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com